Advertisement
AXON vs BEAM
Which Stock Would AI Choose? Axon Enterprise (AXON) vs. Beam Therapeutics (BEAM) Stock Comparison
Key Takeaways
- Axon Enterprise (AXON) operates in the public safety technology sector with consistent double-digit revenue growth driven by its connected devices and software ecosystem.
- Beam Therapeutics (BEAM) focuses on precision genetic medicines using base editing, supported by a substantial cash position but reporting ongoing net losses typical of clinical-stage biotechnology firms.
- Recent market activity shows AXON benefiting from steady demand in law enforcement and enterprise solutions, while BEAM experiences volatility tied to pipeline developments and sector sentiment in healthcare.
- Sector exposure differs markedly: AXON aligns with industrials and defense, offering more predictable revenue streams, whereas BEAM operates in biotechnology with higher binary outcomes from clinical trials.
- Relative performance highlights trade-offs between established growth trajectories in public safety versus high-risk, high-reward potential in gene editing therapies.
- Market positioning suggests AXON demonstrates greater stability in recent weeks compared to the more speculative nature of BEAM’s development milestones.
Introduction
Investors and traders often compare stocks across distinct sectors to evaluate relative performance, risk profiles, and growth drivers in evolving market conditions. Axon Enterprise (AXON) and Beam Therapeutics (BEAM) represent contrasting opportunities—one in established public safety technology and the other in early-stage biotechnology. This comparison appeals to those seeking diversification between defensive industrial growth and innovative healthcare plays. Market participants monitoring momentum, sector rotations, and company-specific catalysts may find value in examining how these equities have responded to broader economic and industry trends over recent periods.
AXON Overview and Recent Performance
Axon Enterprise (AXON) develops and sells public safety technology solutions, including conducted energy devices, body-worn cameras, digital evidence management software, and related services. The company serves law enforcement, military, and enterprise customers globally through its Software and Services and Connected Devices segments. In recent market activity, AXON has maintained momentum supported by sustained demand for integrated safety platforms and recurring software revenue. Broader timeframe references indicate continued expansion in AI-enhanced offerings and platform solutions, contributing to resilience amid fluctuating market sentiment. Upcoming quarterly results have drawn attention to operational execution and margin trends in the public safety sector.
BEAM Overview and Recent Performance
Beam Therapeutics (BEAM) is a biotechnology company advancing precision genetic medicines through its proprietary base editing platform. Its pipeline targets hematology conditions such as sickle cell disease and genetic disorders affecting the liver and other organs. The firm maintains a significant cash position to fund ongoing research and development. Recent market activity reflects typical biotechnology volatility influenced by clinical updates, regulatory pathways, and investor appetite for innovative therapies. In broader periods, BEAM has navigated development milestones while reporting net losses consistent with pre-commercial operations, with performance tied to sector-wide sentiment in healthcare innovation.
Trending AI Robots
Tickeron’s Trending AI Robots page curates a selection of high-performing AI trading bots from hundreds available across its platform. These bots analyze thousands of different tickers using varied trading styles, strategies, timeframes, and statistical profiles, with only the most suitable for prevailing market conditions featured in the trending section. Available bots demonstrate performance metrics such as returns reaching up to +241% alongside win rates in the 70–80% range in select cases, powered by adaptive models across multiple sectors and leverage options. All AI trading bots differ in their approaches, risk parameters, and ticker focus, enabling users to review detailed statistics before engagement. Explore the curated options on the Trending AI Robots page for further insights.
Head-to-Head Comparison
Axon Enterprise (AXON) and Beam Therapeutics (BEAM) diverge significantly in business models, with AXON generating revenue from hardware, software subscriptions, and services in the public safety space, contrasted against BEAM’s research-focused approach reliant on future product approvals. Growth drivers for AXON center on recurring contracts and technological integration, while BEAM depends on clinical advancement and partnerships. Recent momentum favors more established revenue visibility at AXON, whereas BEAM contends with higher execution risk inherent to biotechnology development. Risk factors include regulatory and competitive pressures for AXON versus trial outcomes and dilution potential for BEAM. Sector exposure places AXON in industrials with defensive characteristics, while BEAM aligns with healthcare innovation cycles. Market sentiment reflects steadier positioning for the former amid current conditions.
Tickeron AI Verdict
Based on observable factors such as trend consistency in revenue generation, relative stability during recent market activity, and positioning within a more mature sector, Tickeron’s AI would likely assign a higher probabilistic preference to Axon Enterprise (AXON) over Beam Therapeutics (BEAM) at present. The evaluation emphasizes verifiable performance patterns and lower near-term binary risks compared to clinical-stage developments, though outcomes remain subject to evolving conditions and individual portfolio considerations.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AXON is a Buy and BEAM is a Hold.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
AXON’s FA Score shows that 1 FA rating(s) are green whileBEAM’s FA Score has 1 green FA rating(s).
- AXON’s FA Score: 1 green, 4 red.
- BEAM’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
AXON’s TA Score shows that 4 TA indicator(s) are bullish while BEAM’s TA Score has 5 bullish TA indicator(s).
- AXON’s TA Score: 4 bullish, 4 bearish.
- BEAM’s TA Score: 5 bullish, 5 bearish.
Price Growth
AXON (@Aerospace & Defense) experienced а +7.32% price change this week, while BEAM (@Biotechnology) price change was -2.66% for the same time period.
The average weekly price growth across all stocks in the @Aerospace & Defense industry was +3.40%. For the same industry, the average monthly price growth was +9.64%, and the average quarterly price growth was +8.33%.
The average weekly price growth across all stocks in the @Biotechnology industry was +0.51%. For the same industry, the average monthly price growth was -1.43%, and the average quarterly price growth was +2992.28%.
Reported Earning Dates
AXON is expected to report earnings on Nov 10, 2026.
BEAM is expected to report earnings on Nov 09, 2026.
Industries' Descriptions
@Aerospace & Defense (+3.40% weekly)Aerospace & Defense is one of largest industries in the U.S., mainly comprising the following areas: commercial airliners, military aircraft, missiles, space, and general aviation. Focused heavily on research & development, it is also one of the fastest growing industries. Military aircraft has the largest market share in the industry’s sales, followed by space systems, civil aircraft, and missiles. Aerospace exports, directly and indirectly, support more jobs than the export of any other commodity, according to a study by the U.S. Department of Commerce. Boeing Company, Lockheed Martin Corporation and General Electric Company are some of the most prominent players in this space.
@Biotechnology (+0.51% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
| AXON | BEAM | AXON / BEAM | |
| Capitalization | 49.8B | 2.76B | 1,802% |
| EBITDA | 320M | -349.25M | -92% |
| Gain YTD | 7.906 | -3.499 | -226% |
| P/E Ratio | 255.35 | N/A | - |
| Revenue | 2.98B | 164M | 1,819% |
| Total Cash | 737M | 1.21B | 61% |
| Total Debt | 1.83B | 251M | 728% |
AXON | BEAM | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 41 | 57 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 90 Overvalued | 25 Undervalued | |
PROFIT vs RISK RATING 1..100 | 56 | 100 | |
SMR RATING 1..100 | 81 | 93 | |
PRICE GROWTH RATING 1..100 | 39 | 59 | |
P/E GROWTH RATING 1..100 | 21 | 100 | |
SEASONALITY SCORE 1..100 | 50 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
BEAM's Valuation (25) in the null industry is somewhat better than the same rating for AXON (90) in the Biotechnology industry. This means that BEAM’s stock grew somewhat faster than AXON’s over the last 12 months.
AXON's Profit vs Risk Rating (56) in the Biotechnology industry is somewhat better than the same rating for BEAM (100) in the null industry. This means that AXON’s stock grew somewhat faster than BEAM’s over the last 12 months.
AXON's SMR Rating (81) in the Biotechnology industry is in the same range as BEAM (93) in the null industry. This means that AXON’s stock grew similarly to BEAM’s over the last 12 months.
AXON's Price Growth Rating (39) in the Biotechnology industry is in the same range as BEAM (59) in the null industry. This means that AXON’s stock grew similarly to BEAM’s over the last 12 months.
AXON's P/E Growth Rating (21) in the Biotechnology industry is significantly better than the same rating for BEAM (100) in the null industry. This means that AXON’s stock grew significantly faster than BEAM’s over the last 12 months.
| AXON | BEAM | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 62% | 2 days ago 90% |
| Stochastic ODDS (%) | 2 days ago 78% | 2 days ago 88% |
| Momentum ODDS (%) | 2 days ago 85% | 2 days ago 79% |
| MACD ODDS (%) | 2 days ago 70% | 2 days ago 85% |
| TrendWeek ODDS (%) | 2 days ago 76% | 2 days ago 83% |
| TrendMonth ODDS (%) | 2 days ago 73% | 2 days ago 82% |
| Advances ODDS (%) | 5 days ago 74% | 9 days ago 76% |
| Declines ODDS (%) | 17 days ago 70% | 3 days ago 84% |
| BollingerBands ODDS (%) | 2 days ago 66% | 2 days ago 81% |
| Aroon ODDS (%) | N/A | 2 days ago 79% |
Advertisement
BEAM and
Correlation & Price change
A.I.dvisor indicates that over the last year, BEAM has been closely correlated with CRSP. These tickers have moved in lockstep 75% of the time. This A.I.-generated data suggests there is a high statistical probability that if BEAM jumps, then CRSP could also see price increases.
| Ticker / NAME | Correlation To BEAM | 1D Price Change % | ||
|---|---|---|---|---|
| BEAM | 100% | +0.91% | ||
| CRSP - BEAM | 75% Closely correlated | -0.81% | ||
| PRME - BEAM | 64% Loosely correlated | -2.52% | ||
| EDIT - BEAM | 62% Loosely correlated | +0.36% | ||
| NTLA - BEAM | 59% Loosely correlated | +0.68% | ||
| AXON - BEAM | 57% Loosely correlated | -0.45% | ||
More | ||||